Trials / Unknown
UnknownNCT01690338
A Study of Residual Curarization Incidence in China
A Perspective, Multicentre, Randomized，Blind Study of Residual Curarization Incidence in China
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 6,090 (estimated)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.
Detailed description
In the last twenty years, residual curarization in PACU (Post Anesthesia Care Unit) has become a common problem in clinical practice and poses high risk to patients. The residual curarization incidence of Neuromuscular blocking agents (NMBA) varies very much between different studies. These differences indicates the necessity of further study. In China, there is no common view of the harmfulness of residual curarization and its complications. The consensus on the necessity of neuromuscular transmission monitoring and neuromuscular blockade antagonist has not been reached yet. There is also no similar large-scale survey in China. In this case, the investigators conduct this large scale multicentre study, which is designed to learn the incidence of residual curarization and its complications. Further analysis of risk factors will also been made. All these efforts are hoped to fill the data gap and provide reliable evidences for rational use of NMBA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vecuronium Bromide | Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience. |
| DRUG | Rocuronium | Administrative protocol of rocuronium is determined by each caregiver's clinical experience. |
| DRUG | Cisatracurium | Administrative protocol of cisatracurium is determined by each caregiver's clinical experience |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2014-10-01
- Completion
- 2014-12-01
- First posted
- 2012-09-21
- Last updated
- 2013-05-24
Locations
22 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01690338. Inclusion in this directory is not an endorsement.